Advertisement
Screener

Celldex Therapeutics, Inc. (CLDX) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Celldex Therapeutics, Inc. Operating Cash Flow

Celldex Therapeutics, Inc. (CLDX) reported Operating Cash Flow of -$123.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • Celldex Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$57.41M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$65.59M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$63.94M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$48.63M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$210.94M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$157.78M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$107.29M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$103.73M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$57.41M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$123.00M
10-Q · filed 2026-08-06
-$186.94M
derived: sum of 3 quarters · filed 2026-08-06
-$235.57M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$65.59M
10-Q · filed 2026-05-07
-$129.53M
derived: sum of 2 quarters · filed 2026-05-07
-$178.16M
derived: sum of 3 quarters · filed 2026-05-07
-$222.16M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$63.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$112.57M
derived: sum of 2 quarters · filed 2026-02-25
-$156.57M
derived: sum of 3 quarters · filed 2026-08-06
-$210.94M
10-K · filed 2026-02-25
2025-09-30-$48.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$92.63M
derived: sum of 2 quarters · filed 2026-08-06
-$147.00M
10-Q · filed 2025-11-10
-$179.48M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$44.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$98.38M
10-Q · filed 2026-08-06
-$130.85M
derived: sum of 3 quarters · filed 2026-08-06
-$186.19M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$54.37M
10-Q · filed 2026-05-07
-$86.85M
derived: sum of 2 quarters · filed 2026-05-07
-$142.19M
derived: sum of 3 quarters · filed 2026-05-07
-$171.51M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$32.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$87.81M
derived: sum of 2 quarters · filed 2026-02-25
-$117.14M
derived: sum of 3 quarters · filed 2026-02-25
-$157.78M
10-K · filed 2026-02-25
2024-09-30-$55.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$84.66M
derived: sum of 2 quarters · filed 2025-11-10
-$125.30M
10-Q · filed 2025-11-10
-$157.84M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30-$29.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$69.97M
10-Q · filed 2025-08-07
-$102.50M
derived: sum of 3 quarters · filed 2026-02-25
-$121.49M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31-$40.64M
10-Q · filed 2025-05-08
-$73.17M
derived: sum of 2 quarters · filed 2026-02-25
-$92.16M
derived: sum of 3 quarters · filed 2026-02-25
-$119.36M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31-$32.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$51.53M
derived: sum of 2 quarters · filed 2026-02-25
-$78.72M
derived: sum of 3 quarters · filed 2026-02-25
-$107.29M
10-K · filed 2026-02-25
2023-09-30-$18.99M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
-$46.19M
derived: sum of 2 quarters · filed 2024-11-06
-$74.76M
10-Q · filed 2024-11-06
-$96.52M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30-$27.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$55.77M
10-Q · filed 2024-08-08
-$77.53M
derived: sum of 3 quarters · filed 2025-02-27
-$112.72M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31-$28.57M
10-Q · filed 2024-05-06
-$50.33M
derived: sum of 2 quarters · filed 2025-02-27
-$85.52M
derived: sum of 3 quarters · filed 2025-02-27
-$107.77M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31-$21.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
-$56.95M
derived: sum of 2 quarters · filed 2025-02-27
-$79.20M
derived: sum of 3 quarters · filed 2025-02-27
-$103.73M
10-K · filed 2025-02-27
2022-09-30-$35.19M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
-$57.44M
derived: sum of 2 quarters · filed 2023-11-02
-$81.97M
10-Q · filed 2023-11-02
-$96.49M
derived: sum of 4 quarters · filed 2024-02-26
2022-06-30-$22.24M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
-$46.78M
10-Q · filed 2023-08-08
-$61.30M
derived: sum of 3 quarters · filed 2024-02-26
-$77.67M
derived: sum of 4 quarters · filed 2024-02-26
2022-03-31-$24.53M
10-Q · filed 2023-05-04
-$39.06M
derived: sum of 2 quarters · filed 2024-02-26
-$55.43M
derived: sum of 3 quarters · filed 2024-02-26
-$67.36M
derived: sum of 4 quarters · filed 2024-02-26
2021-12-31-$14.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26
-$30.89M
derived: sum of 2 quarters · filed 2024-02-26
-$42.83M
derived: sum of 3 quarters · filed 2024-02-26
-$60.91M
10-K · filed 2024-02-26
2021-09-30-$16.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$28.30M
derived: sum of 2 quarters · filed 2022-11-09
-$46.39M
10-Q · filed 2022-11-09
-$51.60M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30-$11.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
-$30.01M
10-Q · filed 2022-08-08
-$35.23M
derived: sum of 3 quarters · filed 2023-02-28
-$47.09M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31-$18.08M
10-Q · filed 2022-05-05
-$23.30M
derived: sum of 2 quarters · filed 2023-02-28
-$35.16M
derived: sum of 3 quarters · filed 2023-02-28
-$46.38M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31-$5.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$17.07M
derived: sum of 2 quarters · filed 2023-02-28
-$28.29M
derived: sum of 3 quarters · filed 2023-02-28
-$40.40M
10-K · filed 2023-02-28
2020-09-30-$11.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
-$23.08M
derived: sum of 2 quarters · filed 2021-11-09
-$35.19M
10-Q · filed 2021-11-09
-$46.19M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30-$11.22M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
-$23.33M
10-Q · filed 2021-08-05
-$34.33M
derived: sum of 3 quarters · filed 2022-02-28
-$45.47M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31-$12.11M
10-Q · filed 2021-05-06
-$23.11M
derived: sum of 2 quarters · filed 2022-02-28
-$34.25M
derived: sum of 3 quarters · filed 2022-02-28
-$45.29M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31-$11.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
-$22.14M
derived: sum of 2 quarters · filed 2022-02-28
-$33.18M
derived: sum of 3 quarters · filed 2022-02-28
-$46.41M
10-K · filed 2022-02-28
2019-09-30-$11.14M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$22.18M
derived: sum of 2 quarters · filed 2020-11-05
-$35.41M
10-Q · filed 2020-11-05
-$50.84M
derived: sum of 4 quarters · filed 2021-03-29
2019-06-30-$11.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$24.27M
10-Q · filed 2020-08-06
-$39.70M
derived: sum of 3 quarters · filed 2021-03-29
-$54.09M
derived: sum of 4 quarters · filed 2021-03-29
2019-03-31-$13.23M
10-Q · filed 2020-05-06
-$28.66M
derived: sum of 2 quarters · filed 2021-03-29
-$43.05M
derived: sum of 3 quarters · filed 2021-03-29
-$60.45M
derived: sum of 4 quarters · filed 2021-03-29
2018-12-31-$15.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
-$29.82M
derived: sum of 2 quarters · filed 2021-03-29
-$47.21M
derived: sum of 3 quarters · filed 2021-03-29
-$75.23M
10-K · filed 2021-03-29
2018-09-30-$14.39M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$31.78M
derived: sum of 2 quarters · filed 2019-11-12
-$59.80M
10-Q · filed 2019-11-12
-$79.33M
derived: sum of 4 quarters · filed 2020-03-26
2018-06-30-$17.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
-$45.42M
10-Q · filed 2019-08-07
-$64.94M
derived: sum of 3 quarters · filed 2020-03-26
-$89.30M
derived: sum of 4 quarters · filed 2020-03-26
2018-03-31-$28.02M
10-Q · filed 2019-05-07
-$47.54M
derived: sum of 2 quarters · filed 2020-03-26
-$71.90M
derived: sum of 3 quarters · filed 2020-03-26
-$92.69M
derived: sum of 4 quarters · filed 2020-03-26
2017-12-31-$19.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26
-$43.88M
derived: sum of 2 quarters · filed 2020-03-26
-$64.67M
derived: sum of 3 quarters · filed 2020-03-26
-$99.93M
10-K · filed 2020-03-26
2017-09-30-$24.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
-$45.15M
derived: sum of 2 quarters · filed 2018-11-07
-$80.41M
10-Q · filed 2018-11-07
-$100.76M
derived: sum of 4 quarters · filed 2019-03-07
2017-06-30-$20.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
-$56.05M
10-Q · filed 2018-08-08
-$76.40M
derived: sum of 3 quarters · filed 2019-03-07
-$100.35M
derived: sum of 4 quarters · filed 2019-03-07
2017-03-31-$35.26M
10-Q · filed 2018-05-10
-$55.61M
derived: sum of 2 quarters · filed 2019-03-07
-$79.57M
derived: sum of 3 quarters · filed 2019-03-07
2016-12-31-$20.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
-$44.30M
derived: sum of 2 quarters · filed 2019-03-07
-$113.04M
10-K · filed 2019-03-07
2016-09-30-$23.95M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
-$92.69M
10-Q · filed 2017-11-07
2016-06-30-$68.73M
10-Q · filed 2017-08-08
2015-12-31-$98.89M
10-K · filed 2018-03-07
2011-06-30-$18.23M
10-Q · filed 2011-08-04
2010-06-30-$16.61M
10-Q · filed 2011-08-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEOGEN CORP (NEOG)United States$2.979B-247.49
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93